Company announces results of first trial of wearable COPD monitor

Image of Sylvee lung function monitor and phone app

California-based health tech startup Samay announced the results of the first trial for Sylvee, its AI-assisted, wearable device and platform to monitor lung function in COPD patients.

The device continuously measures air trapping and other metrics of respiratory function in patients at home. The study was conducted in partnership with the Pulmonary, Critical Care & Sleep Disorders Institute of South Florida.

In the study, Samay’s platform detected air trapping (RV/TLC) — an early predictor of COPD exacerbations — with 83% accuracy against hospital pulmonary function tests (PFTs). It also diagnosed COPD with 90% accuracy and registered statistically significant associations in medication efficacy during pre- and post-bronchodilation PFTs.

Samay tested 110 patients with COPD, asthma and healthy controls using the prototype wearable device to measure lung acoustic resonance, paired with a mobile app and a research portal.

"Our platform continuously captures pulmonary function data, including early COPD diagnostic biomarkers and predictors of exacerbations," said Maria Artunduaga, MD, MPH, MTM, Samay's founder and CEO. "Our vision is to enable clinicians to intervene early and monitor frequent exacerbators closely, decreasing hospitalizations."

 

More in COPD
Page 1 of 13
Next Page